News

Greater uptake of hepatitis C medication may help improve the health of Medicaid enrollees and reduce the economic burden of untreated hepatitis C on the U.S. healthcare system, the authors said.

In this final part of a three-part video series, Managed Healthcare Executive® Managing Editor Peter Wehrwein recently interviewed Kulleni Gebreyes, M.D., director of Deloitte's new Health Equity Institute about her career, healthcare disparities and equity issues and the work of the institute.

The combination bamlanivimab and etesevimab can resume use and distribution to treat mild-to-moderate COVID-19 but only in states where variants resistant to the therapy are low.

The resulting spike in telehealth use exceeded expectations, with an 11,718% increase in remote Medicare visits between March and April 2020.

In this second of a three-part video series, Managed Healthcare Executive® Managing Editor Peter Wehrwein recently interviewed Kulleni Gebreyes, M.D., director of Deloitte's new Health Equity Institute about her career, healthcare disparities and equity issues and the work of the institute.

Tecentriq loses indication, Xarelto is approved for reduce risks of cardiovascular events, Tibsovo is approved for rare cancer, Skytrofa is a new, once-weekly growth hormone, and supplemental application is filed Orencia graft-versus-host disease.

In this first of a three-part video series, Managed Healthcare Executive® Managing Editor Peter Wehrwein recently interviewed Kulleni Gebreyes, M.D., director of Deloitte's new Health Equity Institute about her career, healthcare disparities and equity issues and the work of the institute.

Employees are willing to change jobs to receive better coverage for specialty medications.

Organizations should prepare for massive updates to quality measurement and reimbursement in 2023, while simultaneously addressing cost measurement in 2022.

The update indicates there is a serious risk of dehydration and is contraindicated in children.

Bluebook Rx is a new solution that helps employers and plan sponsors better understand and optimize their prescription drug spending.

In this second part of a three-part video series, Briana Contreras, associate editor of MHE, spoke with Dr. Maria Hernandez, founder and CEO of Impact4Health. Maria shared not only how healthcare inequities remain to be an issue and what needs to be addressed, but also the progress that has been made over time through awareness, conversations and laws, especially due to the heightened awareness of inequities caused from the COVID-19 pandemic and the tragic deaths of George Floyd, Breonna Taylor and many more - which have now occurred over a year ago.

In this first part of a three-part video series, Briana Contreras, associate editor of MHE, spoke with Dr. Maria Hernandez, founder and CEO of Impact4Health. Maria shared not only how healthcare inequities remain to be an issue and what needs to be addressed, but also the progress that has been made over time through awareness, conversations and laws, especially due to the heightened awareness of inequities caused from the COVID-19 pandemic and the tragic deaths of George Floyd, Breonna Taylor and many more - which have now occurred over a year ago.

The new model indicates a small initial impact on new drugs coming to the market, but an impact that grows over time.

Public insurers such as Medicaid, especially in states that expanded coverage under the ACA, kept people insured.

This is the seventh year in a row the program increased savings.

Study results reported in JAMA Network Open show that financial incentives are only modestly effective in getting more people to get way screened for colorectal cancer.

The transition from treating patients at a provider’s site to delivering care in the home and community requires two things: an ability to incorporate social determinants of health into the care coordination process and the inclusion of value-based care and community-based organizations as compensated care delivery partners in VBC networks.

The liquid therapy to treat hypothyroidism now comes in 15 different dosage strengths in single-use packaging.

ICER calculations using real-world data would result in major price cuts of three therapies — Takhzyro, Haegarda, and Cinryze — if they were to meet commonly used cost-effective thresholds.

U.S. Preventive Services Task Force (USPSTF) screening recommendations for diabetes, prediabetes need to be coupled with public health measures, argues accompanying editorial.

Xarelto is now indicated to help reduce the risks of major cardiovascular events in patients with coronary artery disease and major thrombotic vascular events.

Congress wants to cut $1.5 trillion from innovative companies and threaten the loss of one million jobs in order to fund a multi-trillion-dollar spending bill, according to Pharmaceutical Research and Manufacturers of America President and CEO Stephen J. Ubl. This approach would undermine the ability to develop new treatments and jeopardize patient access to life-saving medicines.

Preliminary research shows Anplag could be repurposed as a heart failure treatment at a lower cost.

A wave of vaccine mandates has started. The FDA's full OK today may have an effect on the unvaccinated with a wait-and-see attitude and could, according to one expert, open the door to off-label use of the vaccine by clinicians.

The drug savings and greater use of generics that ACO proponents hope for did not materailize.

Survey highlights level of compliance preparedness and increasing skepticism towards new regulations.

Now called Comirnaty, the vaccine is approved for those 16 years and older.

Increasing the practice of evidence-based care is vital to improving the quality and efficiency of care in the U.S. To push more providers to adopt evidence-based medicine, we must reward high-quality patient outcomes - not high volumes.